Clinical Trial

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-25; most recent amendment 2026-03-04.
Trial Details
NCT Number NCT06196827
Lead Sponsor Innostellar Biotherapeutics Co.,Ltd
Conditions Inherited Retinal Dystrophy Associated With RPE65 Mutations
Enrollment 9 participants
Start Date 2022-07-02
Primary Completion 2023-12-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-06